PRNewsWire
01 Oct 2026, 12:52 UTC · 1h ago
Verdict
Headline takes no side. We score DGX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
The Haystack MRD test demonstrated 100% specificity and 100% sensitivity at 3-year follow-up, and 83.3% sensitivity at 5-year follow-up for predicting colorectal cancer recurrence.
Newpublished Oct 1, 2026
So whatSuperiority over the CEA biomarker (88.9% vs 11.1% sensitivity) positions the test for wider clinical adoption and increased test volumes starting in FY2027.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The study validated Haystack MRD's analytical performance across 23 different solid tumor types.
Newpublished Oct 1, 2026
So whatExpanding the addressable market beyond colorectal cancer to 22 additional tumor types significantly increases the potential total addressable market (TAM) and long-term revenue CAGR.
More positive than 79% of claims this week
In a real-world cohort, Haystack MRD detected ctDNA across 27 solid tumor types, with 42% of positive results falling below 0.5 mean ctDNA molecules/mL.
Newpublished Oct 1, 2026
More positive than 67% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company's Haystack MRD test demonstrated high sensitivity and specificity in clinical trials for detecting cancer recurrence.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
6h ago
−0.1%
Price flat so far
$232.82 vs $233.07 close before publication (Sep 30) · not market-adjusted
DGX chart →
